- $416.08m
- $421.58m
- $824.50m
Myriad Genetics falls after preliminary Q4 revenue misses estimates
Brief: Myriad Genetics Announces 5 Year Strategic Alliance With University Of Texas
Brief: Myriad Genetics Provides Update On Discussions With Unitedhealthcare Regarding Medical Policy For Pharmacogenetic Testing
Brief: Myriad Genetics Expands Board Of Directors With Election Of Mark S. Davis As New Board Member
Brief: Myriad Genetics Says Settlement Was Approved By The Court In Myriad Genetics, Inc. Stockholder Derivative Litigation
Myriad Genetics Inc reports results for the quarter ended in September 30 - Earnings Summary
Brief: Myriad Genetics Q3 Operating Income USD -20 Million
Brief: Myriad Genetics Expects Q3 Revenue About $210 Million-$212 Million
Brief: Myriad Genetics Announces Five Research Collaborations To Study The Use Of Mrd Testing In Breast Cancer
Brief: Myriad Genetics Announces Third Patent Granted For Molecular Residual Disease (Mrd) With Early Priority Date
Brief: Myriad Genetics Identifies Disparities Between Genesight & Non-Genesight Control Group In Baseline Hospital Resource Utilization & Costs In Analysis
Brief: Myriad Genetics Q2 Operating Income USD -36.5 Million
Myriad Genetics Inc expected to post a loss of 1 cent a share - Earnings Preview
Myriad Genetics Inc expected to post a loss of 1 cent a share - Earnings Preview
U.S. RESEARCH ROUNDUP-BlackRock, Goldman Sachs, Netflix
Brief: Myriad Genetics Announces Second Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
U.S. RESEARCH ROUNDUP-Carnival, FedEx, Micron Technology
Brief: Myriad Genetics Collaborates With GSK To Improve Access To HRD Testing In 9 Countries
Myriad Genetics Inc reports results for the quarter ended in March - Earnings Summary